# A Study to Evaluate the Efficacy and Safety of HCP1004 in Chronic Low-Back Pain Patients

> **NCT06595004** · PHASE3 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 310 (actual)

## Conditions studied

- Chronic Low-back Pain

## Interventions

- **DRUG:** HCP1004
- **DRUG:** RLD2401

## Key facts

- **NCT ID:** NCT06595004
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-11-22
- **Primary completion:** 2025-06-18
- **Final completion:** 2025-06-18
- **Target enrollment:** 310 (ACTUAL)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06595004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06595004, "A Study to Evaluate the Efficacy and Safety of HCP1004 in Chronic Low-Back Pain Patients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06595004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*